{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:56:50Z","timestamp":1773194210169,"version":"3.50.1"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0025_s_020_w2aab3b7b1b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d3156347e374_w2aab3b7b1b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is a treatment option for patients with peritoneal metastases shown to provide improved overall survival for appropriately selected patients. However, the availability and utilization of this treatment remains limited. The aim of this survey-based study was to evaluate factors influencing physician treatment choices for peritoneal metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0025_s_021_w2aab3b7b1b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d3156347e383_w2aab3b7b1b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>Surveys were mailed to medical oncologists and surgeons in Virginia, Maryland, and Washington, D.C. Survey questions evaluated access to HIPEC centers, prior experience with referral to HIPEC centers, opinions regarding efficacy, and knowledge regarding outcomes of CRS and HIPEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0025_s_022_w2aab3b7b1b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d3156347e392_w2aab3b7b1b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>Surveys were mailed to 2279 physicians; 116 eligible surveys were returned. Seventy-five percent of respondents would consider referral to a HIPEC center for appendiceal peritoneal metastasis, while only 50% would consider it for colon cancer and peritoneal mesothelioma. The most common reason for never referring a patient to a HIPEC center was lack of access to a HIPEC specialist (47%) followed by perceived lack of evidence for the treatment modality (31%). Five-year survival after CRS and HIPEC was underestimated while 30-day mortality was overestimated by more than half of respondents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0025_s_023_w2aab3b7b1b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d3156347e401_w2aab3b7b1b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>Referral to HIPEC centers is underutilized among community physicians in practice. Limited access to HIPEC experts is the most common cause for lack of referral, followed by a perception of insufficient evidence for this treatment approach. Lack of familiarity with data regarding outcomes impacts referral patterns and treatment choices. Possible actions to increase awareness and appropriate utilization of CRS and HIPEC are suggested.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0025","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T10:58:22Z","timestamp":1522839502000},"source":"Crossref","is-referenced-by-count":19,"title":["Practice patterns, attitudes, and knowledge among physicians regarding cytoreductive surgery and HIPEC for patients with peritoneal metastases"],"prefix":"10.1515","volume":"3","author":[{"given":"Tyler","family":"Bernaiche","sequence":"first","affiliation":[{"name":"Department of Surgery , Inova Fairfax Medical Campus , 3300 Gallows Road, 22042 , Falls Church , VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Emery","sequence":"additional","affiliation":[{"name":"Department of Surgery , Inova Fairfax Medical Campus , 3300 Gallows Road, 22042 , Falls Church , VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Bijelic","sequence":"additional","affiliation":[{"name":"Department of Surgery , Inova Fairfax Medical Campus , 3300 Gallows Road, 22042 , Falls Church , VA, USA"},{"name":"Inova Schar Cancer Institute , Falls Church , VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"2025120909183251069_j_pp-2017-0025_ref_001_w2aab3b7b1b1b6b1ab1b6b1Aa","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.1064096810.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909183251069_j_pp-2017-0025_ref_002_w2aab3b7b1b1b6b1ab1b6b2Aa","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545\u201350.1244506410.1046\/j.1365-2168.2002.02274.x"},{"key":"2025120909183251069_j_pp-2017-0025_ref_003_w2aab3b7b1b1b6b1ab1b6b3Aa","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449\u201356.2261497610.1200\/JCO.2011.39.7166"},{"key":"2025120909183251069_j_pp-2017-0025_ref_004_w2aab3b7b1b1b6b1ab1b6b4Aa","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135.1910372810.1200\/JCO.2008.19.7160"},{"key":"2025120909183251069_j_pp-2017-0025_ref_005_w2aab3b7b1b1b6b1ab1b6b5Aa","unstructured":"Li Y, Yu Y, Liu Y. Report on the 9th international congress on peritoneal surface malignancies. Cancer Biol Med 2014;11:281\u20134."},{"key":"2025120909183251069_j_pp-2017-0025_ref_006_w2aab3b7b1b1b6b1ab1b6b6Aa","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicenter retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435\u201343.10.1016\/j.ejso.2013.09.03024209430"},{"key":"2025120909183251069_j_pp-2017-0025_ref_007_w2aab3b7b1b1b6b1ab1b6b7Aa","unstructured":"Van Driel W, Sikorska K, Van Leeuwen JS, Schreuder H, Hermans R, De Hingh I, et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol 2017;35(15_suppl):5519."},{"key":"2025120909183251069_j_pp-2017-0025_ref_008_w2aab3b7b1b1b6b1ab1b6b8Aa","doi-asserted-by":"crossref","unstructured":"Sleightholm R, Foster J, Smith L, Ceelen W, Deraco M, Yildirim Y, et al. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score. J Surg Oncol 2016;114:779\u201384.10.1002\/jso.2440627792292","DOI":"10.1002\/jso.24406"},{"key":"2025120909183251069_j_pp-2017-0025_ref_009_w2aab3b7b1b1b6b1ab1b6b9Aa","unstructured":"Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 2014;218:573\u201385.2449124410.1016\/j.jamcollsurg.2013.12.013"},{"key":"2025120909183251069_j_pp-2017-0025_ref_010_w2aab3b7b1b1b6b1ab1b6c10Aa","unstructured":"Spiegle G, Schmocker S, Huang H, Victor JC, Law C, McCart JA, et al. Physicians\u2019 awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. Can J Surg 2013;56:237\u201342.10.1503\/cjs.00391223883493"},{"key":"2025120909183251069_j_pp-2017-0025_ref_011_w2aab3b7b1b1b6b1ab1b6c11Aa","unstructured":"The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys, 9th ed. AAPOR, Oakbrook terrace, IL."},{"key":"2025120909183251069_j_pp-2017-0025_ref_012_w2aab3b7b1b1b6b1ab1b6c12Aa","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2015."},{"key":"2025120909183251069_j_pp-2017-0025_ref_013_w2aab3b7b1b1b6b1ab1b6c13Aa","unstructured":"Ye YJ, Shen ZL, Sun XT, Wang ZF, Shen DH, Liu HJ, et al. Impact of multidisciplinary team working on the management of colorectal cancer. Chin Med J 2012;125:172\u20137.22340540"},{"key":"2025120909183251069_j_pp-2017-0025_ref_014_w2aab3b7b1b1b6b1ab1b6c14Aa","unstructured":"Wood JJ, Metcalfe C, Paes A, Sylvestor P, Durdey P, Thomas MG, et al. An evaluation of treatment decisions at a colorectal cancer multi-disciplinary team. Colorectal Dis 2008;10:769\u201372.10.1111\/j.1463-1318.2007.01464.x"},{"key":"2025120909183251069_j_pp-2017-0025_ref_015_w2aab3b7b1b1b6b1ab1b6c15Aa","doi-asserted-by":"crossref","unstructured":"Fernando C, Frizelle F, Wakeman C, Frampton C, Robinson B. Colorectal multidisciplinary meeting audit to determine patient benefit. ANZ J Surg 2015 Nov 3. doi:10.1111\/ans.13366. Epub ahead of print.26525919","DOI":"10.1111\/ans.13366"},{"key":"2025120909183251069_j_pp-2017-0025_ref_016_w2aab3b7b1b1b6b1ab1b6c16Aa","doi-asserted-by":"crossref","unstructured":"Basta YL, Bolle S, Fockens P, Tytgat KM. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol 2017;9:2669\u201378.","DOI":"10.1245\/s10434-017-5833-3"},{"key":"2025120909183251069_j_pp-2017-0025_ref_017_w2aab3b7b1b1b6b1ab1b6c17Aa","unstructured":"Braam HJW, Boerma D, Wiezer MJ, Van Ramshorst B. Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists. Int J Clin Oncol 2015;20:928\u201334.10.1007\/s10147-015-0816-5"},{"key":"2025120909183251069_j_pp-2017-0025_ref_018_w2aab3b7b1b1b6b1ab1b6c18Aa","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686\u201393.10.1245\/s10434-014-3978-x25124472"},{"key":"2025120909183251069_j_pp-2017-0025_ref_019_w2aab3b7b1b1b6b1ab1b6c19Aa","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u201342.1991786210.1200\/JCO.2009.23.9640"},{"key":"2025120909183251069_j_pp-2017-0025_ref_020_w2aab3b7b1b1b6b1ab1b6c20Aa","unstructured":"Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg 2014;149:170\u20135.10.1001\/jamasurg.2013.364024352601"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/3\/1\/article-20170025.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0025\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0025\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:25:15Z","timestamp":1765272315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0025\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,30]]},"published-print":{"date-parts":[[2018,3,26]]}},"alternative-id":["10.1515\/pp-2017-0025"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0025","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"article-number":"20170025"}}